Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adult neural stem cell therapy - Microbot Medical

Drug Profile

Adult neural stem cell therapy - Microbot Medical

Alternative Names: hCNS-SC; HuCNS-SC; HuCNS-SC cells; Neurodegenerative disorders stem cell therapy - Microbot Medical

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator StemCells
  • Developer Microbot Medical; Oregon Health & Science University; StemCells; University of California at Irvine
  • Class Neuroprotectants; Stem cell therapies
  • Mechanism of Action Cell replacements; Myelin protein stimulants; Neurogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Alzheimer's disease; Retinal disorders

Highest Development Phases

  • Phase II Spinal cord injuries
  • Suspended Alzheimer's disease; Dry age-related macular degeneration
  • No development reported Pelizaeus-Merzbacher disease; Stroke
  • Discontinued Neuronal ceroid lipofuscinosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Pelizaeus-Merzbacher-disease in USA (Intracerebral, Implant)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Stroke in USA (Parenteral)
  • 28 Nov 2016 StemCells has been acquired and merged into Microbot Medical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top